A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

501

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: Selinexor (combination therapy)
DRUG: Selinexor (combination therapy)
DRUG: Selinexor (combination therapy)
DRUG: Placebo matching for Selinexor (combination therapy)
DRUG: Rituximab (combination therapy)
DRUG: Rituximab (combination therapy)
DRUG: Gemcitabine (combination therapy)
DRUG: Dexamethasone (combination therapy)
DRUG: Cisplatin (combination therapy)
DRUG: Selinexor (continuous therapy)
DRUG: Placebo matching for Selinexor (continuous therapy)

Sponsor

Karyopharm Therapeutics Inc